Efficacy and Safety of PG-530742 in the Treatment of Mild to Moderate Knee Osteoarthritis

Phase 2 Completed 395 enrolled Procter and Gamble

RandomizedParallel-groupDouble-blindTreatment

Summary

Matrix metalloproteinases (MMPs) have been implicated in the cartilage degradation. PG-530742 inhibits some MMPs, potentially limiting cartilage degradation and disease progression. This study will test the efficacy and safety of PG-530742 in the treatment of mild to moderate knee osteoarthritis.

Timeline

Start: 2002-07
Primary completion: 2004-02
Completion: 2004-02

Outcome

Missed primary endpoint

paper After 1 year of treatment, no statistically significant difference was observed between placebo and PG-116800 PMID 17958901 ↗

Publications

Krzeski P, Buckland-Wright C, Balint G, Cline GA, Stoner K, Lyon R, Beary J, Aronstein WS, Spector TD. Development of musculoskeletal toxicity without clear benefit after administration of PG-116800, a matrix metalloproteinase inhibitor, to patients with knee osteoarthritis: a randomized, 12-month, double-blind, placebo-controlled study. Arthritis Res Ther. 2007;9(5):R109. doi: 10.1186/ar2315.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PG-530742	Unknown	25 mg	Oral
Subject	PG-530742	Unknown	50 mg	Oral
Subject	PG-530742	Unknown	100 mg	Oral
Subject	PG-530742	Unknown	200 mg	Oral